Skip to main content
Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease

Fig. 4

Fexofenadine inhibits the propagation of α-syn in PFF-injected mice. a Schematic diagram of in vivo PFF injection experiment. b IHC of pSer129 α-syn in PFF or PFF + Fexo. Arrows indicate positive inclusion bodies. Scale bar indicates 50 μm. c The number of pSer129 α-syn in ipsilateral and contralateral regions. Values are derived from the analysis of data collected from PFF (n = 6) or PFF + Fexo (n = 7) groups at 4 weeks post-injection. ***p < 0.001, **p < 0.01, *p < 0.05, one-way ANOVA with Tukey’s multiple comparison test. d The brain atlas indicates the distribution of pSer129 α-syn-positive inclusion bodies (red dots) in coronal sections from mice brains with PFF or PFF + Fexo groups at 4 weeks post-injection. See Additional file 1: Fig. S1 for abbreviations used

Back to article page